SAVANNAH, Ga., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Health Discovery Corporation (``HDC'') (OTC BB:HDVY.OB - News) today announced that the RT-PCR assay for the four genes comprising HDC's recently commercialized gene-based molecular diagnostic test for prostate cancer, which is currently available at Clarient Inc.'s (NasdaqCM:CLRT - News) Clinical Laboratory, can be successfully used in urine samples for gene testing.
